The authors analysed the results of therapy of 72 oral mucosa cancer patients who had received combined modality radiotherapy using at the stage of intracavitary irradiation sources of 60Co of a raised dose rate on the afterloading AGAT unit. Forty four patients received irradiation as part of combined modality therapy, 28 were treated by irradiation only. Two variants of combined modality radiotherapy were employed: gamma-beam and intracavitary irradiation was given simultaneously on the same day; consecutively alternating gamma-beam (on the 1st day) and intracavitary (on the 2nd day) irradiation. The most effective summary focal dose values in preoperative combined irradiation were 40-45 Gy (with the ratio of the contribution of gamma-beam therapeutic doses of 30-35 Gy and intracavitary doses of 10-15 Gy) and in radiotherapy used alone 75-80 Gy (with the ratio of irradiation components being 50-55 Gy and 25-30 Gy respectively). Complete tumor resorption in combined modality radiotherapy used independently was achieved in 19 out of 28 patients (67.8%). In combined treatment tumor regression by more than 50% after preoperative irradiation was achieved in 65.9% of the patients. Tumor recurrences were noted in 5 of 44 (11.3%) patients in combined treatment and in 3 out of 19 (15.7%) in radiotherapy used alone. Five-year survival rates calculated with the help of life tables were 55.7 +/- 10% after combined treatment and 48.7 +/- 11% after radiotherapy used alone. Clinical evidence indicated the advantages of combined modality radiotherapy with simultaneous intracavitary and gamma-beam irradiation.
Download full-text PDF |
Source |
---|
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Anti-amyloid immunotherapies modestly slow disease progression in early symptomatic AD; addition of other therapeutic modalities may be necessary to achieve larger treatment effects. Therapies that directly target tau can potentially produce substantial clinical benefit because the accumulation of insoluble tau protein is strongly correlated with the progression of AD. Which tau therapies are likely to be efficacious, whether or not to combine them with anti-amyloid therapies, and which individuals are most likely to benefit are important unresolved questions that would require multiple parallel design trials to answer.
View Article and Find Full Text PDFBackground: Recent anti-amyloid mAb trial results demonstrate slowing of Alzheimer's disease progression, but to date do not fully halt or reverse this progression. Optimization of anti-amyloid therapy (timing and duration of intervention, modality, combinations, biomarker guidance) is limited by incomplete understanding of the disease, such as relationship between amyloid and tau pathways. Mechanistic Alzheimer's progression modeling investigated how amyloid and tau pathologies are connected in driving progression.
View Article and Find Full Text PDFClin J Pain
January 2025
Department of Anesthesiology Critical Care Medicine, The Saban Research Institute at Children's Hospital Los Angeles, The Biobehavioral Pain Lab.
Objectives: Chronic pain is a leading cause of morbidity in children and adolescents globally but can be managed with a combination of traditional Western medicine and integrative medicine (IM) practices. This combination has improved various critical health outcomes, such as quality-of-life, sleep, pain, anxiety, and healthcare utilization. These IM practices include acupuncture, yoga, biofeedback, massage, mindfulness, or any combination of these modalities.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Johns Hopkins University, Baltimore, MD, USA.
Background: Phenotyping Alzheimer's Disease (AD) can be crucial to providing personalized treatment. Several studies have analyzed the use of digital biomarkers to characterize a subject's behavior, usually obtained from a single modality, such as speech. However, combining several modalities in a single study has not been deeply studied.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!